TY - JOUR T1 - <strong>Clinical management intent of Ga68 PSMA PET/CT imaging in prostate cancer: an Australian multicentre study.</strong> JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 706 LP - 706 VL - 58 IS - supplement 1 AU - Paul Roach AU - Roslyn Francis AU - Louise Emmett AU - Michael McCarthy AU - Andrew Scott Y1 - 2017/05/01 UR - http://jnm.snmjournals.org/content/58/supplement_1/706.abstract N2 - 706Objectives: Ga68-Prostate Specific Membrane Antigen (PSMA) PET/CT is being increasingly used in the assessment of patients with prostate cancer. The aim of this study was to determine its impact in the clinical management of patients with prostate cancer.Methods: This prospective multicentre study assessed the management intent of patients undergoing Ga68 PSMA PET/CT in 4 Australian centres. Referring medical specialists completed a management intent survey prior to their patients undergoing Ga68 PSMA PET/CT scanning. A follow up survey was then completed by the referring specialist once the results of the Ga68-PSMA PET/CT results were made available. The primary question was to determine whether (and to what degree) their management plan would change based on the PSMA PET/CT scan findings. Results: For the period between January 2015 and June 2016, 431 patients had pre- and post-Ga68 PSMA management plans completed by their referring specialists. Scans were performed for primary staging in 25% patients and for a rising PSA following surgery and/or radiotherapy in 75% of patients. On the post PSMA survey, the clinicians indicated that the scan led to a change in planned management in 51% of patients. A greater management change was noted for patients with an indication of biochemical recurrence (post-surgery 64%, post radiation therapy 69%), compared with primary staging (23%). Preliminary analysis showed that the PSMA scan detected disease that was not previously suspected in the prostate bed (30% of patients), locoregional lymph nodes (36% of patients) and distant disease (16% of patients). Conclusion: Ga68 PSMA PET/CT scans detect previously unsuspected disease and change planned clinical management in a high proportion of patients with prostate cancer. The impact was much greater in patients with biochemical recurrence post surgery or radiation therapy, compared with primary staging. Research Support: ER -